

PART I	AN INTRODUCTION TO IMMUNOBIOLOGY AND INNATE IMMUNITY	
Chapter 1	Basic Concepts in Immunology	1
Chapter 2	Innate Immunity	37
PART II	THE RECOGNITION OF ANTIGEN	
Chapter 3	Antigen Recognition by B-cell and T-cell Receptors	103
Chapter 4	The Generation of Lymphocyte Antigen Receptors	135
Chapter 5	Antigen Presentation to T Lymphocytes	169
PART III	THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES	
Chapter 6	Signaling Through Immune System Receptors	203
Chapter 7	The Development and Survival of Lymphocytes	241
PART IV	THE ADAPTIVE IMMUNE RESPONSE	
Chapter 8	T Cell-Mediated Immunity	319
Chapter 9	The Humoral Immune Response	367
Chapter 10	Adaptive Immunity to Infection	409
PART V	THE IMMUNE SYSTEM IN HEALTH AND DISEASE	
Chapter 11	Failures of Host Defense Mechanisms	461
Chapter 12	Allergy and Hypersensitivity	517
Chapter 13	Autoimmunity and Transplantation	557
Chapter 14	Manipulation of the Immune Response	613
PART VI	THE ORIGINS OF IMMUNE RESPONSES	
Chapter 15	Evolution of the Innate Immune System	665
Appendix I	Immunologists' Toolbox	683
Appendix II	CD Antigens	731
Appendix III	Cytokines and their Receptors	747
Appendix IV	Chemokines and their Receptors	750
Appendix V	Immunological Constants	751
Biographies		752
Glossary		753
Index		778

Detailed Contents

Part I

AN INTRODUCTION TO IMMUNO-BIOLOGY AND INNATE IMMUNITY

Chapter 1 Basic Concepts in Immunology 1

The components of the immune system. 2

- 1-1 The white blood cells of the immune system derive from precursors in the bone marrow. 3
- 1-2 Lymphocytes mature in the bone marrow or the thymus. 7
- 1-3 The peripheral lymphoid organs are specialized to trap antigen-bearing dendritic cells, to allow initiation of adaptive immune responses, and to provide signals that sustain recirculating lymphocytes. 8
- 1-4 Lymphocytes circulate between blood and lymph. 10
- Summary. 11

Principles of innate and adaptive immunity. 12

- 1-5 Most infectious agents induce inflammatory responses by activating innate immunity. 12
- 1-6 Activation of specialized antigen-presenting cells is a necessary first step for induction of adaptive immunity. 13
- 1-7 The innate immune system provides an initial discrimination between self and nonself. 14
- 1-8 Lymphocytes activated by antigen give rise to clones of antigen-specific cells that mediate adaptive immunity. 15
- 1-9 Clonal selection of lymphocytes is the central principle of adaptive immunity. 16
- 1-10 The structure of the antibody molecule illustrates the central puzzle of adaptive immunity. 17
- 1-11 Each developing lymphocyte generates a unique antigen receptor by rearranging its receptor gene segments. 17
- 1-12 Development and survival of lymphocytes are determined by signals received through their antigen receptors. 18
- 1-13 Lymphocytes proliferate in response to antigen in peripheral lymphoid organs, generating effector cells and immunological memory. 19
- 1-14 Interaction with other cells as well as with antigen is necessary for lymphocyte activation. 21
- Summary. 22

The recognition and effector mechanisms of adaptive immunity. 24

- 1-15 Antibodies deal with extracellular forms of pathogens and their toxic products. 25
- 1-16 T cells are needed to control intracellular pathogens and to activate B-cell responses to most antigens. 26
- 1-17 T cells are specialized to recognize foreign antigens as peptide fragments bound to proteins of the major histocompatibility complex. 28
- 1-18 Two major types of T cell recognize peptides bound to proteins of two different classes of MHC molecule. 29

1-19	Defects in the immune system result in increased susceptibility to infection.	31
1-20	Understanding adaptive immune responses is important for the control of allergies, autoimmune disease, and organ graft rejection.	32
1-21	Vaccination is the most effective means of controlling infectious diseases.	33
	Summary.	33
	Summary to Chapter 1.	34

Chapter 2 Innate Immunity **37**

The front line of host defense. **38**

2-1	Infectious agents must overcome innate host defenses to establish a focus of infection.	39
2-2	The epithelial surfaces of the body make up the first lines of defense against infection.	40
2-3	After entering tissues, many pathogens are recognized, ingested, and killed by phagocytes.	42
2-4	Pathogen recognition and tissue damage initiate an inflammatory response.	45
	Summary.	48

Pattern recognition in the innate immune system. **48**

2-5	Receptors with specificity for pathogen molecules recognize patterns of repeating structural motifs.	49
2-6	Receptors on phagocytes can signal the presence of pathogens.	51
2-7	Each of the 10 Toll-like receptors in humans recognizes a particular molecular structure that is present in many pathogens.	51
2-8	The effects of bacterial lipopolysaccharide on macrophages are mediated by CD14 binding to TLR-4.	52
2-9	Activation of Toll-like receptors triggers the production of pro-inflammatory cytokines and chemokines, and the expression of co-stimulatory molecules.	53
	Summary.	54

The complement system and innate immunity. **55**

2-10	Complement is a system of plasma proteins that interacts with pathogens to mark them for destruction by phagocytes.	56
2-11	The classical pathway is initiated by activation of the C1 complex.	58
2-12	The mannose-binding lectin pathway is homologous to the classical pathway.	60
2-13	Complement activation is largely confined to the surface on which it is initiated.	61
2-14	Hydrolysis of C3 causes initiation of the alternative pathway of complement.	61
2-15	Surface-bound C3 convertase deposits large numbers of C3b fragments on pathogen surfaces and generates C5 convertase activity.	66

2-16	Ingestion of complement-tagged pathogens by phagocytes is mediated by receptors for the bound complement proteins.	66
2-17	Small fragments of some complement proteins can initiate a local inflammatory response.	68
2-18	The terminal complement proteins polymerize to form pores in membranes that can kill certain pathogens.	69
2-19	Complement control proteins regulate all three pathways of complement activation and protect the host from its destructive effects.	70
	Summary.	75

Induced innate responses to infection. 75

2-20	Activated macrophages secrete a range of cytokines that have a variety of local and distant effects.	76
2-21	Chemokines released by phagocytes and dendritic cells recruit cells to sites of infection.	77
2-22	Cell-adhesion molecules control interactions between leukocytes and endothelial cells during an inflammatory response.	80
2-23	Neutrophils make up the first wave of cells that cross the blood vessel wall to enter inflammatory sites.	82
2-24	Tumor necrosis factor- α is an important cytokine that triggers local containment of infection but induces shock when released systemically.	84
2-25	Cytokines released by phagocytes activate the acute-phase response.	85
2-26	Interferons induced by viral infection make several contributions to host defense.	87
2-27	NK cells are activated by interferons and macrophage-derived cytokines to serve as an early defense against certain intracellular infections.	89
2-28	NK cells possess receptors for self molecules that prevent their activation by uninfected cells.	90
2-29	Several lymphocyte subpopulations behave as innate-like lymphocytes.	93
	Summary.	95
	Summary to Chapter 2.	95

Part II THE RECOGNITION OF ANTIGEN

Chapter 3 Antigen Recognition by B-cell and T-cell Receptors 103

The structure of a typical antibody molecule. 104

3-1	IgG antibodies consist of four polypeptide chains.	105
3-2	Immunoglobulin heavy and light chains are composed of constant and variable regions.	106
3-3	The antibody molecule can readily be cleaved into functionally distinct fragments.	106
3-4	The immunoglobulin molecule is flexible, especially at the hinge region.	108
3-5	The domains of an immunoglobulin molecule have similar structures.	109
	Summary.	110

The interaction of the antibody molecule with specific antigen. 110

3-6	Localized regions of hypervariable sequence form the antigen-binding site.	110
3-7	Antibodies bind antigens via contacts with amino acids in CDRs, but the details of binding depend upon the size and shape of the antigen.	112
3-8	Antibodies bind to conformational shapes on the surfaces of antigens.	112
3-9	Antigen–antibody interactions involve a variety of forces.	113
	Summary.	115

Antigen recognition by T cells. 115

3-10	The antigen receptor on T cells is very similar to a Fab fragment of immunoglobulin.	116
3-11	A T-cell receptor recognizes antigen in the form of a complex of a foreign peptide bound to an MHC molecule.	117
3-12	T cells with different functions are distinguished by CD4 and CD8 cell-surface proteins and recognize peptides bound to different classes of MHC molecule.	118
3-13	The two classes of MHC molecule are expressed differentially on cells.	120
3-14	The two classes of MHC molecule have distinct subunit structures but similar three-dimensional structures.	121
3-15	Peptides are stably bound to MHC molecules, and also serve to stabilize the MHC molecule on the cell surface.	124
3-16	MHC class I molecules bind short peptides of 8–10 amino acids by both ends.	125
3-17	The length of the peptides bound by MHC class II molecules is not constrained.	126
3-18	The crystal structures of several MHC:peptide:T-cell receptor complexes all show the same T-cell receptor orientation over the MHC:peptide complex.	128
3-19	A distinct subset of T cells bears an alternative receptor made up of γ and δ chains.	129
	Summary.	130
	Summary to Chapter 3.	130

Chapter 4 The Generation of Lymphocyte Antigen Receptors 135

The generation of diversity in immunoglobulins. 136

4-1	Immunoglobulin genes are rearranged in antibody-producing cells.	136
4-2	Complete genes that encode a V region are generated by the somatic recombination of separate gene segments.	137
4-3	For each immunoglobulin chain, multiple V-region gene segments are present on one contiguous stretch of chromosome.	138
4-4	Rearrangement of V, D, and J gene segments is guided by flanking DNA sequences.	140
4-5	The reaction that recombines V, D, and J gene segments involves both lymphocyte-specific and ubiquitous DNA-modifying enzymes.	142
4-6	The diversity of the immunoglobulin repertoire is generated by four main processes.	144
4-7	The multiple inherited gene segments are used in different combinations.	144
4-8	Variable addition and subtraction of nucleotides at the junctions between gene segments contributes to the diversity of the third hypervariable region.	145

4-9	Rearranged V genes are further diversified by somatic hypermutation.	146
4-10	In some species, most immunoglobulin gene diversification occurs after gene rearrangement.	148
	Summary.	148

T-cell receptor gene rearrangement. 149

4-11	The T-cell receptor gene segments are arranged in a similar pattern to immunoglobulin gene segments and are rearranged by the same enzymes.	149
4-12	T-cell receptors concentrate diversity in the third hypervariable region.	151
4-13	$\gamma\delta$ T-cell receptors are also generated by gene rearrangement.	152
4-14	Somatic hypermutation does not generate diversity in T-cell receptors.	153
	Summary.	153

Structural variation in immunoglobulin constant regions. 154

4-15	Transmembrane and secreted forms of immunoglobulin are generated from alternative heavy-chain transcripts.	154
4-16	The immunoglobulin heavy-chain isotypes are distinguished by the structure of their constant regions.	156
4-17	Mature naive B cells express both IgM and IgD at their surface.	157
4-18	Isotype switching enables the same assembled V_H exon to be associated with different C_H genes in the course of an immune response.	158
4-19	Antibody C regions confer functional specialization.	160
4-20	IgM and IgA can form polymers.	162
4-21	Various differences between immunoglobulins can be detected by antibodies.	163
	Summary.	164
	Summary to Chapter 4.	164

Chapter 5 Antigen Presentation to T Lymphocytes 169

The generation of T-cell receptor ligands. 170

5-1	The MHC class I and class II molecules deliver peptides to the cell surface from two distinct intracellular compartments.	170
5-2	Peptides that bind to MHC class I molecules are actively transported from the cytosol to the endoplasmic reticulum.	171
5-3	Peptides for transport into the endoplasmic reticulum are generated in the cytosol.	172
5-4	Newly synthesized MHC class I molecules are retained in the endoplasmic reticulum until they bind peptide.	174
5-5	Peptides presented by MHC class II molecules are generated in acidified endocytic vesicles.	176
5-6	The invariant chain directs newly synthesized MHC class II molecules to acidified intracellular vesicles.	178
5-7	A specialized MHC class II-like molecule catalyzes loading of MHC class II molecules with peptides.	179
5-8	Stable binding of peptides by MHC molecules provides effective antigen presentation at the cell surface.	181
	Summary.	182

The major histocompatibility complex and its functions. 183

5-9	Many proteins involved in antigen processing and presentation are encoded by genes within the major histocompatibility complex.	183
5-10	A variety of genes with specialized functions in immunity are also encoded in the MHC.	185
5-11	Specialized MHC class I molecules act as ligands for the activation and inhibition of NK cells.	187
5-12	The protein products of MHC class I and class II genes are highly polymorphic.	187
5-13	MHC polymorphism affects antigen recognition by T cells by influencing both peptide binding and the contacts between T-cell receptor and MHC molecule.	189
5-14	Nonself MHC molecules are recognized by 1–10% of T cells.	192
5-15	Many T cells respond to superantigens.	193
5-16	MHC polymorphism extends the range of antigens to which the immune system can respond.	194
5-17	MHC polymorphism is generated by several different genetic processes.	195
5-18	Some peptides and lipids generated in the endocytic pathway can be bound by MHC class I-like molecules that are encoded outside the MHC.	196
	Summary.	197
	Summary to Chapter 5.	197

Part III THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES

Chapter 6	Signaling Through Immune System Receptors	203
	General principles of transmembrane signaling.	204
6-1	Binding of antigen leads to clustering of antigen receptors on lymphocytes.	204
6-2	Clustering of antigen receptors leads to activation of intracellular signal molecules.	206
6-3	Receptors and signaling molecules concentrate in specialized regions of the cell membrane.	206
6-4	Phosphorylation of receptor cytoplasmic tails by tyrosine kinases concentrates intracellular signaling molecules around the receptors.	208
6-5	Intracellular signaling components recruited to activated receptors transmit the signal onward from the membrane and amplify it.	209
6-6	Small G proteins activate a protein kinase cascade that transmits the signal to the nucleus.	211
	Summary.	212
	Antigen receptor structure and signaling pathways.	212
6-7	The variable chains of lymphocyte antigen receptors are associated with invariant accessory chains that perform the signaling function of the receptor.	213
6-8	The ITAMs associated with the B-cell and T-cell receptors are phosphorylated by protein tyrosine kinases of the Src family.	214
6-9	Antigen receptor signaling is enhanced by co-receptors that bind the same ligand.	216

6-10	Fully phosphorylated ITAMs bind the protein tyrosine kinases Syk and ZAP-70 and enable them to be activated.	218
6-11	Downstream events are mediated by proteins that associate with the phosphorylated tyrosines, and bind to and activate other proteins.	218
6-12	Antigen recognition leads ultimately to the induction of new gene synthesis by activating transcription factors.	221
6-13	Signals from the antigen receptor alter the cytoskeleton to produce changes in cell shape, motility, and secretion.	224
6-14	Not all ligands for the T-cell receptor produce a similar response.	224
6-15	Other receptors on leukocytes also use ITAMs to signal activation.	226
6-16	Antigen-receptor signaling can be inhibited by receptors associated with ITIMs.	226
	Summary.	227

Other signaling pathways that contribute to lymphocyte behavior. **228**

6-17	Microbes and their products release NF κ B from its site in the cytosol through an ancient pathway of host defense against infection.	228
6-18	Bacterial peptides, mediators of inflammatory responses, and chemokines signal through members of the G-protein-coupled receptor family.	230
6-19	Cytokines signal lymphocytes by binding to cytokine receptors and triggering Janus kinases to phosphorylate and activate STAT proteins.	231
6-20	Programmed cell death of activated lymphocytes is triggered mainly through the receptor Fas.	232
6-21	Lymphocyte survival is maintained by a balance between death-promoting and death-inhibiting members of the Bcl-2 family of proteins.	233
6-22	Homeostasis of lymphocyte populations is maintained by signals that lymphocytes are continually receiving through their antigen receptors.	234
	Summary.	236
	Summary to Chapter 6.	236

Chapter 7 The Development and Survival of Lymphocytes **241**

Generation of lymphocytes in bone marrow and thymus. **244**

7-1	Lymphocyte development occurs in specialized environments and is regulated by signals from the environment along with the somatic rearrangement of the antigen-receptor genes.	245
7-2	B cells develop in the bone marrow with the help of stromal cells and achieve maturity in peripheral lymphoid organs.	247
7-3	Stages in B-cell development are distinguished by the expression of immunoglobulin chains and particular cell-surface proteins.	248
7-4	T cells also originate in the bone marrow, but all the important events in their development occur in the thymus.	251
7-5	T-cell precursors proliferate extensively in the thymus but most die there.	253
7-6	Successive stages in the development of thymocytes are marked by changes in cell-surface molecules.	254

7-7	Thymocytes at different developmental stages are found in distinct parts of the thymus.	256
	Summary.	257
The rearrangement of antigen-receptor gene segments controls lymphocyte development.		258
7-8	B cells undergo a programmed series of gene rearrangements in the bone marrow.	258
7-9	Successful rearrangement of heavy-chain immunoglobulin gene segments leads to the formation of a pre-B-cell receptor that halts further V_H to DJ_H rearrangement and triggers the cell to divide.	260
7-10	Rearrangement at the immunoglobulin light-chain locus leads to cell-surface expression of the B-cell receptor.	262
7-11	The expression of proteins regulating immunoglobulin gene rearrangement and function is developmentally programmed.	264
7-12	T cells in the thymus undergo a series of gene segment rearrangements similar to those of B cells.	267
7-13	Successful rearrangement at the β -chain locus and synthesis of a β chain leads to the production of a pre-T-cell receptor that triggers cell proliferation and cessation of β -chain gene rearrangement.	267
7-14	T-cell α -chain genes undergo successive rearrangements until positive selection or cell death intervenes.	270
7-15	T cells with $\alpha:\beta$ or $\gamma:\delta$ receptors arise from a common progenitor.	272
7-16	T cells expressing particular γ - and δ -chain V regions arise in an ordered sequence early in life.	273
	Summary.	275
Interaction with self antigens selects some lymphocytes for survival but eliminates others.		275
7-17	Immature B cells that bind self antigens undergo further receptor rearrangement, die, or are inactivated.	276
7-18	The MHC type of the thymic stroma selects a repertoire of mature T cells that can recognize foreign antigens presented by the same MHC type.	280
7-19	Only thymocytes whose receptors interact with self-MHC: self-peptide complexes can survive and mature.	282
7-20	Positive selection acts on a repertoire of receptors with inherent specificity for MHC molecules.	283
7-21	Positive selection coordinates the expression of CD4 or CD8 with the specificity of the T-cell receptor and the potential effector functions of the T cell.	283
7-22	Thymic cortical epithelial cells mediate positive selection of developing thymocytes.	285
7-23	T cells that react strongly with ubiquitous self antigens are deleted in the thymus.	287
7-24	Negative selection is driven most efficiently by bone marrow derived antigen-presenting cells.	289
7-25	The specificity and/or the strength of signals for negative and positive selection must differ.	290
	Summary.	292
Survival and maturation of lymphocytes in peripheral lymphoid tissues.		293
7-26	Lymphocytes are found in particular locations in peripheral lymphoid tissues.	293
7-27	The development and organization of peripheral lymphoid tissues is controlled by tumor necrosis factor family molecules, and the homing of lymphocytes is mediated by chemokines.	295

7-28	The further development and homeostasis of peripheral lymphocytes is determined via cytokines and by signals that lymphocytes continually receive through their antigen receptors.	297
7-29	Lymphocytes that encounter sufficient quantities of self antigens for the first time in the periphery are eliminated or inactivated.	298
7-30	Most immature B cells arriving in the spleen are short-lived and require cytokines and positive signals through the B-cell receptor for maturation and survival.	299
7-31	The specificity of the B-cell receptor is important in determining the differentiation and survival of B cells in the periphery.	300
7-32	The life-span of T cells in the periphery is determined by cytokines as well as ongoing contact with self-peptide: self-MHC complexes similar to those that initially selected them.	303
7-33	B-cell tumors often occupy the same site as their normal counterparts.	304
7-34	A range of tumors of immune system cells throws light on different stages of T-cell development.	306
7-35	Malignant lymphocyte tumors frequently carry chromosomal translocations that join immunoglobulin loci to genes that regulate cell growth.	307
	Summary.	308
	Summary to Chapter 7.	309

Part IV

THE ADAPTIVE IMMUNE RESPONSE

Chapter 8 T Cell-Mediated Immunity 319

The production of armed effector T cells. 321

8-1	T-cell responses are initiated in peripheral lymphoid organs by activated antigen-presenting cells.	321
8-2	Naive T cells sample the MHC:peptide complexes on the surface of antigen-presenting cells as they migrate through peripheral lymphoid tissue.	323
8-3	Lymphocyte migration, activation, and effector function depend on cell-cell interactions mediated by cell-adhesion molecules.	324
8-4	The initial interaction of T cells with antigen-presenting cells is mediated by cell-adhesion molecules.	327
8-5	Both specific antigen and co-stimulatory signals provided by the same antigen-presenting cell are required for the clonal expansion of naive T cells.	328
8-6	Dendritic cells specialize in ingesting antigen and activating naive T cells.	331
8-7	Macrophages are scavenger cells that can be induced by pathogens to present foreign antigens to naive T cells.	334
8-8	B cells are highly efficient at presenting antigens that bind to their surface immunoglobulin.	335
8-9	Activated T cells synthesize the T-cell growth factor interleukin-2 and its receptor.	337
8-10	The co-stimulatory signal is necessary for the synthesis and secretion of IL-2.	338
8-11	Antigen recognition in the absence of co-stimulation leads to the inactivation of peripheral T cells.	338

8-12	Proliferating T cells differentiate into armed effector T cells that do not require co-stimulation to act.	339
8-13	The differentiation of CD4 T cells into T _H 1 or T _H 2 cells determines whether humoral or cell-mediated immunity will predominate.	341
8-14	Naive CD8 T cells can be activated in different ways to become armed cytotoxic effector cells.	341
	Summary.	342
General properties of armed effector T cells.		343
8-15	Effector T-cell interactions with target cells are initiated by antigen-nonspecific cell-adhesion molecules.	344
8-16	Binding of the T-cell receptor complex directs the release of effector molecules and focuses them on the target cell.	344
8-17	The effector functions of T cells are determined by the array of effector molecules that they produce.	346
8-18	Cytokines can act locally or at a distance.	347
8-19	Cytokines and their receptors fall into distinct families of structurally related proteins.	349
8-20	The TNF family of cytokines are trimeric proteins that are usually associated with the cell surface.	350
	Summary.	351
T cell-mediated cytotoxicity.		351
8-21	Cytotoxic T cells can induce target cells to undergo programmed cell death.	352
8-22	Cytotoxic effector proteins that trigger apoptosis are contained in the granules of CD8 cytotoxic T cells.	353
8-23	Activated CD8 T cells and some CD4 effector T cells express Fas ligand, which can also activate apoptosis.	355
8-24	Cytotoxic T cells are selective and serial killers of targets expressing specific antigen.	355
8-25	Cytotoxic T cells also act by releasing cytokines.	356
	Summary.	356
Macrophage activation by armed CD4 T_H1 cells.		357
8-26	Armed T _H 1 cells have a central role in macrophage activation.	357
8-27	The production of cytokines and membrane-associated molecules by armed CD4 T _H 1 cells requires new RNA and protein synthesis.	358
8-28	Activation of macrophages by armed T _H 1 cells promotes microbial killing and must be tightly regulated to avoid tissue damage.	358
8-29	T _H 1 cells coordinate the host response to intracellular pathogens.	359
	Summary.	361
	Summary to Chapter 8.	361
Chapter 9 The Humoral Immune Response		367
B-cell activation by armed helper T cells.		369
9-1	The humoral immune response is initiated when B cells that bind antigen are signaled by helper T cells or by certain microbial antigens alone.	369
9-2	Armed helper T cells activate B cells that recognize the same antigen.	370
9-3	Antigenic peptides bound to self MHC class II molecules	

	trigger armed helper T cells to make membrane-bound and secreted molecules that can activate a B cell.	372
9-4	Isotype switching in thymus-dependent responses requires expression of CD40 ligand by the helper T cell and is directed by cytokines.	373
9-5	Antigen-binding B cells are trapped in the T-cell zone of secondary lymphoid tissues and are activated by encounter with armed helper T cells.	375
9-6	The second phase of the primary B-cell immune response occurs when activated B cells migrate to follicles and proliferate to form germinal centers.	377
9-7	Germinal center B cells undergo V-region somatic hypermutation, and cells with mutations that improve affinity for antigen are selected.	379
9-8	Ligation of the B-cell receptor and CD40, together with direct contact with T cells, are all required to sustain germinal center B cells.	382
9-9	Surviving germinal center B cells differentiate into either plasma cells or memory cells.	383
9-10	B-cell responses to bacterial antigens with intrinsic ability to activate B cells do not require T-cell help.	383
9-11	B-cell responses to bacterial polysaccharides do not require peptide-specific T-cell help.	385
	Summary.	387

The distribution and functions of immunoglobulin isotypes. **387**

9-12	Antibodies of different isotype operate in distinct places and have distinct effector functions.	388
9-13	Transport proteins that bind to the Fc regions of antibodies carry particular isotypes across epithelial barriers.	389
9-14	High-affinity IgG and IgA antibodies can neutralize bacterial toxins.	392
9-15	High-affinity IgG and IgA antibodies can inhibit the infectivity of viruses.	393
9-16	Antibodies can block the adherence of bacteria to host cells.	394
9-17	Antibody:antigen complexes activate the classical pathway of complement by binding to C1q.	395
9-18	Complement receptors are important in the removal of immune complexes from the circulation.	396
	Summary.	397

The destruction of antibody-coated pathogens via Fc receptors. **398**

9-19	The Fc receptors of accessory cells are signaling receptors specific for immunoglobulins of different isotypes.	398
9-20	Fc receptors on phagocytes are activated by antibodies bound to the surface of pathogens and enable the phagocytes to ingest and destroy pathogens.	399
9-21	Fc receptors activate NK cells to destroy antibody-coated targets.	401
9-22	Mast cells, basophils, and activated eosinophils bind IgE antibody via the high-affinity Fc ϵ receptor.	402
9-23	IgE-mediated activation of accessory cells has an important role in resistance to parasite infection.	403
	Summary.	404
	Summary to Chapter 9.	405

Chapter 10	Adaptive Immunity to Infection	409
	Infectious agents and how they cause disease.	410
10-1	The course of an infection can be divided into several distinct phases.	410
10-2	Infectious diseases are caused by diverse living agents that replicate in their hosts.	412
	Summary.	416
	The course of the adaptive response to infection.	416
10-3	The nonspecific responses of innate immunity are necessary for an adaptive immune response to be initiated.	417
10-4	An adaptive immune response is initiated when circulating T cells encounter their corresponding antigen in draining lymphoid tissues and become activated.	418
10-5	Cytokines made in the early phases of an infection influence the functional differentiation of CD4 T cells.	420
10-6	Distinct subsets of T cells can regulate the growth and effector functions of other T-cell subsets.	423
10-7	The nature and amount of antigenic peptide can also affect the differentiation of CD4 T cells.	424
10-8	Armed effector T cells are guided to sites of infection by chemokines and newly expressed adhesion molecules.	425
10-9	Antibody responses develop in lymphoid tissues under the direction of armed helper T cells.	427
10-10	Antibody responses are sustained in medullary cords and bone marrow.	428
10-11	The effector mechanisms used to clear an infection depend on the infectious agent.	429
10-12	Resolution of an infection is accompanied by the death of most of the effector cells and the generation of memory cells.	431
	Summary.	431
	The mucosal immune system.	432
10-13	Mucosa-associated lymphoid tissue is located in anatomically defined microcompartments throughout the gut.	433
10-14	The trafficking of lymphocytes within different compartments of the immune system is controlled by tissue-specific adhesion and chemokine interactions.	434
10-15	The mucosal immune system contains a distinctive repertoire of lymphocytes.	436
10-16	Secretory IgA is the antibody isotype associated with the mucosal immune system.	438
10-17	Most antigens presented to the mucosal immune system induce tolerance.	439
10-18	The mucosal immune system can mount an immune response to the normal bacterial flora of the gut.	439
10-19	Enteric pathogens cause a local inflammatory response and the development of protective immunity.	440
10-20	Infection by <i>Helicobacter pylori</i> causes a chronic inflammatory response, which can cause peptic ulcers, carcinoma of the stomach, and unusual lymphoid tumors.	443
10-21	In the absence of inflammatory stimuli, the normal response of the mucosal immune system to foreign antigens is tolerance.	444
	Summary.	445
	Immunological memory.	446

10-22	Immunological memory is long-lived after infection or vaccination.	446
10-23	Both clonal expansion and clonal differentiation contribute to immunological memory in B cells.	447
10-24	Repeated immunization leads to increasing affinity of antibody owing to somatic hypermutation and selection by antigen in germinal centers.	449
10-25	Memory T cells are increased in frequency and have distinct activation requirements and cell-surface proteins that distinguish them from armed effector T cells.	450
10-26	In immune individuals, secondary and subsequent responses are mediated mainly by memory lymphocytes.	451
	Summary.	454
	Summary to Chapter 10.	454

Part V

THE IMMUNE SYSTEM IN HEALTH AND DISEASE

Chapter 11 Failures of Host Defense Mechanisms 461

Pathogens have evolved various means of evading or subverting normal host defenses. 462

11-1	Antigenic variation allows pathogens to escape from immunity.	462
11-2	Some viruses persist <i>in vivo</i> by ceasing to replicate until immunity wanes.	465
11-3	Some pathogens resist destruction by host defense mechanisms or exploit them for their own purposes.	466
11-4	Immunosuppression or inappropriate immune responses can contribute to persistent disease.	468
11-5	Immune responses can contribute directly to pathogenesis.	470
	Summary.	470

Immunodeficiency diseases. 470

11-6	A history of repeated infections suggests a diagnosis of immunodeficiency.	471
11-7	Inherited immunodeficiency diseases are caused by recessive gene defects.	472
11-8	The main effect of low levels of antibody is an inability to clear extracellular bacteria.	474
11-9	T-cell defects can also result in low antibody levels.	476
11-10	Defects in complement components cause defective humoral immune function.	478
11-11	Defects in phagocytic cells permit widespread bacterial infections.	479
11-12	Defects in T-cell function result in severe combined immunodeficiencies.	480
11-13	Defective T-cell signaling, cytokine production, or cytokine action can cause immunodeficiency.	483
11-14	The normal pathways for host defense against intracellular bacteria are illustrated by genetic deficiencies of IFN- γ and IL-12 and their receptors.	485
11-15	X-linked lymphoproliferative syndrome is associated with fatal infection by Epstein-Barr virus and with the development of lymphomas.	486
11-16	Genetic abnormalities in the secretory cytotoxic pathway of lymphocytes cause uncontrolled lymphoproliferation and inflammatory responses to viral infections.	487

11-17	Bone marrow transplantation or gene therapy can be useful to correct genetic defects.	488
11-18	Secondary immunodeficiencies are major predisposing causes of infection and death.	489
	Summary.	490

Acquired immune deficiency syndrome. 491

11-19	Most individuals infected with HIV progress over time to AIDS.	492
11-20	HIV is a retrovirus that infects CD4 T cells, dendritic cells, and macrophages.	494
11-21	Genetic deficiency of the macrophage chemokine co-receptor for HIV confers resistance to HIV infection <i>in vivo</i> .	496
11-22	HIV RNA is transcribed by viral reverse transcriptase into DNA that integrates into the host cell genome.	497
11-23	Transcription of the HIV provirus depends on host-cell transcription factors induced upon the activation of infected T cells.	499
11-24	Drugs that block HIV replication lead to a rapid decrease in titer of infectious virus and an increase in CD4 T cells.	500
11-25	HIV accumulates many mutations in the course of infection in a single individual and drug treatment is soon followed by the outgrowth of drug-resistant variants of the virus.	501
11-26	Lymphoid tissue is the major reservoir of HIV infection.	502
11-27	An immune response controls but does not eliminate HIV.	503
11-28	HIV infection leads to low levels of CD4 T cells, increased susceptibility to opportunistic infection, and eventually to death.	505
11-29	Vaccination against HIV is an attractive solution but poses many difficulties.	506
11-30	Prevention and education are one way in which the spread of HIV and AIDS can be controlled.	507
	Summary.	508
	Summary to Chapter 11.	508

Chapter 12 Allergy and Hypersensitivity 517

Sensitization and the production of IgE. 519

12-1	Allergens are often delivered transmucosally at low dose, a route that favors IgE production.	519
12-2	Enzymes are frequent triggers of allergy.	520
12-3	Class switching to IgE in B lymphocytes is favored by specific signals.	521
12-4	Both genetic and environmental factors contribute to the development of IgE-mediated allergy.	523
	Summary.	527

Effector mechanisms in allergic reactions. 527

12-5	Most IgE is cell-bound and engages effector mechanisms of the immune system by different pathways from other antibody isotypes.	528
12-6	Mast cells reside in tissues and orchestrate allergic reactions.	529
12-7	Eosinophils are normally under tight control to prevent inappropriate toxic responses.	530
12-8	Eosinophils and basophils cause inflammation and tissue damage in allergic reactions.	532
12-9	Allergic reactions can be divided into immediate and late-phase responses.	533

12-10	The clinical effects of allergic reactions vary according to the site of mast-cell activation.	534
12-11	Allergen inhalation is associated with the development of rhinitis and asthma.	535
12-12	Skin allergy is manifest as urticaria or chronic eczema.	538
12-13	Allergy to foods causes symptoms limited to the gut and systemic reactions.	539
12-14	Allergy can be treated by inhibiting either IgE production or the effector pathways activated by cross-linking of cell-surface IgE.	539
	Summary.	541

Hypersensitivity diseases. 542

12-15	Innocuous antigens can cause type II hypersensitivity reactions in susceptible individuals by binding to the surfaces of circulating blood cells.	542
12-16	Systemic disease caused by immune-complex formation can follow the administration of large quantities of poorly catabolized antigens.	542
12-17	Delayed-type hypersensitivity reactions are mediated by T _H 1 cells and CD8 cytotoxic T cells.	544
12-18	Mutation or genetic variation in the molecular regulators of inflammation can cause hypersensitive inflammatory responses resulting in 'autoinflammatory disease'.	547
	Summary.	550
	Summary to Chapter 12.	550

Chapter 13 Autoimmunity and Transplantation 557

The nature of immune responses to self. 557

13-1	A critical function of the immune system is to discriminate self from nonself.	558
13-2	Specific adaptive immune responses to self antigens can cause autoimmune disease.	559
13-3	Autoimmune diseases can be classified into clusters that are typically either organ-specific or systemic.	560
13-4	Multiple limbs of the immune system are typically recruited in autoimmune disease.	561
13-5	Initial loss of tolerance and autoimmunity may evolve to a chronic disease state because of positive feedback from inflammation as well as the inability to clear most self antigens.	564
	Summary.	566

Multiple tolerance mechanisms normally prevent autoimmunity. 566

13-6	Some degree of autoimmunity is the evolutionary price of being able to make effective responses against pathogens.	567
13-7	Central deletion or inactivation of newly formed lymphocytes is the first checkpoint of self-tolerance.	567
13-8	Lymphocytes that bind self antigens with relatively low affinity usually ignore them but in some circumstances become activated.	569
13-9	Antigens in immunologically privileged sites do not induce immune attack but can serve as targets.	570
13-10	Autoreactive T cells that express particular cytokines may be nonpathogenic or suppress pathogenic lymphocytes.	572
13-11	Autoimmune responses can be controlled at various stages by regulatory T cells.	572
13-12	CD4 CD25 T cells are a unique subset of cells that arise in the thymus in response to relatively strong recognition of	

	self antigen.	573
13-13	The mechanisms of regulation are varied and can include cytokine-mediated inhibition, contact-dependent regulation, and cell killing.	574
13-14	Other types of regulatory cell also exist.	575
13-15	Immune responses have natural brakes that tend to limit damage even when autoimmune cells are activated.	576
	Summary.	576
	The genetic and environmental basis of autoimmunity.	578
13-16	Autoimmune diseases have a strong genetic as well as environmental component.	578
13-17	Several approaches have given us insight into the genetic basis of autoimmunity.	579
13-18	Genes that predispose to autoimmunity fall into categories that affect one or more of the layers of tolerance.	580
13-19	MHC genes have an important role in controlling susceptibility to autoimmune disease.	582
13-20	Molecular pathways promoting autoimmunity are potential targets for the therapy of autoimmune disease.	584
13-21	Drugs and toxins can cause autoimmune syndromes.	585
13-22	Infection can lead to autoimmune disease.	585
13-23	Cross-reactivity between self molecules and foreign molecules on pathogens can lead to anti-self responses and autoimmune disease.	586
13-24	Random events may be required for the initiation of autoimmunity.	587
	Summary.	588
	Mechanisms of pathogenesis in autoimmunity.	588
13-25	Antibody and T cells can cause tissue damage in autoimmune disease.	589
13-26	Autoantibodies against blood cells promote their destruction.	590
13-27	The fixation of sublytic doses of complement to cells in tissues stimulates a powerful inflammatory response.	591
13-28	Autoantibodies against receptors cause disease by stimulating or blocking receptor function.	592
13-29	Autoantibodies against extracellular antigens cause inflammatory injury by mechanisms akin to type II and type III hypersensitivity reactions.	593
13-30	T cells specific for self antigens can cause direct tissue injury and have a role in sustained autoantibody responses.	595
	Summary.	595
	Responses to alloantigens and transplant rejection.	596
13-31	Graft rejection is an immunological response mediated primarily by T cells.	597
13-32	Matching donor and recipient at the MHC improves the outcome of transplantation.	598
13-33	In MHC-identical grafts, rejection is caused by peptides from other alloantigens bound to graft MHC molecules.	599
13-34	There are two ways of presenting alloantigens on the transplant to the recipient's T lymphocytes.	600
13-35	Antibodies reacting with endothelium cause hyperacute graft rejection.	602
13-36	Chronic organ rejection is caused by inflammatory vascular injury to the graft.	602
13-37	A variety of organs are transplanted routinely in clinical medicine.	603

13-38	The converse of graft rejection is graft-versus-host disease.	604
13-39	The fetus is an allograft that is tolerated repeatedly.	606
	Summary.	607
	Summary to Chapter 13.	607

Chapter 14 Manipulation of the Immune Response 613

Extrinsic regulation of unwanted immune responses. 614

14-1	Corticosteroids are powerful anti-inflammatory drugs that alter the transcription of many genes.	614
14-2	Cytotoxic drugs cause immunosuppression by killing dividing cells and have serious side-effects.	615
14-3	Cyclosporin A, tacrolimus (FK506), and rapamycin (sirolimus) are powerful immunosuppressive agents that interfere with T-cell signaling.	616
14-4	Immunosuppressive drugs are valuable probes of intracellular signaling pathways in lymphocytes.	617
14-5	Antibodies against cell-surface molecules have been used to remove specific lymphocyte subsets or to inhibit cell function.	619
14-6	Antibodies can be engineered to reduce their immunogenicity in humans.	619
14-7	Monoclonal antibodies can be used to inhibit allograft rejection.	620
14-8	Biological agents can be used to alleviate and suppress autoimmune disease.	622
14-9	Depletion or inhibition of autoreactive lymphocytes can treat autoimmune disease.	624
14-10	Interference with co-stimulatory pathways for the activation of lymphocytes could be a treatment for autoimmune disease.	626
14-11	Modulation of the cytokines expressed by T lymphocytes can inhibit autoimmune disease.	626
14-12	Controlled administration of antigen can be used to manipulate the nature of an antigen-specific response.	628
	Summary.	629

Using the immune response to attack tumors. 630

14-13	The development of transplantable tumors in mice led to the discovery that mice could mount a protective immune response against tumors.	630
14-14	T lymphocytes can recognize specific antigens on human tumors.	631
14-15	Tumors can escape rejection in many ways.	635
14-16	Monoclonal antibodies against tumor antigens, alone or linked to toxins, can control tumor growth.	638
14-17	Enhancing the immunogenicity of tumors holds promise for cancer therapy.	640
	Summary.	642

Manipulating the immune response to fight infection. 642

14-18	There are several requirements for an effective vaccine.	644
14-19	The history of vaccination against <i>Bordetella pertussis</i> illustrates the importance of developing an effective vaccine that is perceived to be safe.	645
14-20	Conjugate vaccines have been developed as a result of understanding how T and B cells collaborate in an immune response.	646
14-21	The use of adjuvants is another important approach to enhancing the immunogenicity of vaccines.	647

14-22	Live-attenuated viral vaccines are usually more potent than 'killed' vaccines and can be made safer by using recombinant DNA technology.	649
14-23	Live-attenuated bacterial vaccines can be developed by selecting nonpathogenic or disabled mutants.	650
14-24	Attenuated microorganisms can serve as vectors for vaccination against many pathogens.	650
14-25	Synthetic peptides of protective antigens can elicit protective immunity.	651
14-26	The route of vaccination is an important determinant of success.	653
14-27	Protective immunity can be induced by injecting DNA encoding microbial antigens and human cytokines into muscle.	653
14-28	The effectiveness of a vaccine can be enhanced by targeting it to sites of antigen presentation.	654
14-29	An important question is whether vaccination can be used therapeutically to control existing chronic infections.	655
14-30	Modulation of the immune system might be used to inhibit immunopathological responses to infectious agents.	656
	Summary.	656
	Summary to Chapter 14.	657

Part VI THE ORIGINS OF IMMUNE RESPONSES

Chapter 15 Evolution of the Immune System 665

Evolution of the innate immune system. 667

15-1	Antimicrobial peptides are likely to be the most ancient immune defenses.	667
15-2	Toll-like receptors may represent the most primitive pathogen-recognition system.	668
15-3	A second recognition system in <i>Drosophila</i> homologous to the mammalian tumor necrosis factor receptor pathway provides protection from Gram-negative bacteria.	670
15-4	An ancestral complement system opsonizes pathogens for uptake by phagocytic cells.	671
15-5	The lectin pathway of complement activation evolved in invertebrates.	672
	Summary.	673

Evolution of the adaptive immune response. 673

15-6	Adaptive immunity appeared abruptly in the cartilaginous fish.	674
15-7	The target of the transposon is likely to have been a gene encoding a cell-surface receptor containing an immunoglobulin-like V domain.	676
15-8	Different species generate immunoglobulin diversity in different ways.	676
15-9	Both $\alpha\beta$ and $\gamma\delta$ T-cell receptors are present in cartilaginous fish.	678
15-10	MHC class I and class II molecules are also first found in the cartilaginous fishes.	678
15-11	Are adaptive immune systems dependent on the emergence of the jaw?	679
	Summary.	680
	Summary to Chapter 15.	680

Appendix I Immunologists' Toolbox **683**

Immunization. **683**

A-1	Haptens.	684
A-2	Routes of immunization.	686
A-3	Effects of antigen dose.	686
A-4	Adjuvants.	686

The detection, measurement, and characterization of antibodies and their use as research and diagnostic tools. **688**

A-5	Affinity chromatography.	689
A-6	Radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and competitive inhibition assay.	689
A-7	Hemagglutination and blood typing.	691
A-8	Precipitin reaction.	692
A-9	Equilibrium dialysis: measurement of antibody affinity and avidity.	693
A-10	Anti-immunoglobulin antibodies.	694
A-11	Coombs tests and the detection of Rhesus incompatibility.	695
A-12	Monoclonal antibodies.	696
A-13	Phage display libraries for antibody V-region production.	697
A-14	Immunofluorescence microscopy.	698
A-15	Immunoelectron microscopy.	700
A-16	Immunohistochemistry.	701
A-17	Immunoprecipitation and co-immunoprecipitation.	701
A-18	Immunoblotting (Western blotting).	702
A-19	Use of antibodies in the isolation and identification of genes and their products.	703

Isolation of lymphocytes. **705**

A-20	Isolation of peripheral blood lymphocytes by Ficoll-Hypaque™ gradient.	705
A-21	Isolation of lymphocytes from tissues other than blood.	705
A-22	Flow cytometry and FACS analysis.	706
A-23	Lymphocyte isolation using antibody-coated magnetic beads.	708
A-24	Isolation of homogeneous T-cell lines.	708

Characterization of lymphocyte specificity, frequency, and function. **709**

A-25	Limiting-dilution culture.	710
A-26	ELISPOT assays.	711
A-27	Identification of functional subsets of T cells by staining for cytokines.	712
A-28	Identification of T-cell receptor specificity using MHC: peptide tetramers.	713

A-29	Assessing the diversity of the T-cell repertoire by 'spectratyping.'	714
A-30	Biosensor assays for measuring the rates of association and disassociation of antigen receptors for their ligands.	714
A-31	Stimulation of lymphocyte proliferation by treatment with polyclonal mitogens or specific antigen.	716
A-32	Measurements of apoptosis by the TUNEL assay.	717
A-33	Assays for cytotoxic T cells.	717
A-34	Assays for CD4 T cells.	717
A-35	DNA microarrays.	718

Detection of immunity *in vivo*. **720**

A-36	Assessment of protective immunity.	720
A-37	Transfer of protective immunity.	720
A-38	The tuberculin test.	721
A-39	Testing for allergic responses.	721
A-40	Assessment of immune responses and immunological competence in humans.	721
A-41	The Arthus reaction.	723

Manipulation of the immune system. **723**

A-42	Adoptive transfer of lymphocytes.	723
A-43	Hematopoietic stem-cell transfers.	724
A-44	<i>In vivo</i> depletion of T cells.	724
A-45	<i>In vivo</i> depletion of B cells.	724
A-46	Transgenic mice.	725
A-47	Gene knockout by targeted disruption.	726

Appendix II CD antigens **731**

Appendix III Cytokines and their receptors **747**

Appendix IV Chemokines and their receptors **750**

Appendix V Immunological constants **751**

Biographies **752**

Glossary **753**

Index **778**